

SECOND SUPPLEMENT DATED 19 DECEMBER 2025
TO THE BASE PROSPECTUS DATED 5 MAY 2025

L'ORÉAL

L'Oréal
€15,000,000,000
Euro Medium Term Note Programme

This second supplement (the "**Second Supplement**") constitutes a supplement to and must be read in conjunction with the base prospectus dated 5 May 2025 (the "**Base Prospectus**") granted approval no. 25-135 on 5 May 2025 by the *Autorité des marchés financiers* (the "**AMF**") as supplemented by the first supplement dated 7 November 2025 granted approval no. 25-434 on 7 November 2025 by the AMF (the "**First Supplement**") prepared by L'Oréal (the "**Issuer**") with respect to its Euro Medium Term Note Programme (the "**Programme**"). The Base Prospectus, as supplemented by the First Supplement and this Second Supplement, constitutes a base prospectus for the purpose of Article 8 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as may be amended from time to time (the "**Prospectus Regulation**").

Application has been made to the AMF in France for approval of this Second Supplement in its capacity as competent authority pursuant to the Prospectus Regulation.

This Second Supplement has been prepared pursuant to Article 23.1 of the Prospectus Regulation for the purposes of (i) increasing the Programme limit from €10,000,000,000 to €15,000,000,000, (ii) incorporating by reference into the Base Prospectus the Issuer's press release dated 8 December 2025 relating to the Issuer's additional investment in Galderma and (iii) updating the "*General Information*" section of the Base Prospectus.

A copy of this Second Supplement will be available on the websites of (i) the Issuer (www.loreal-finance.com) and (ii) the AMF (www.amf-france.org).

Terms defined in the Base Prospectus have the same meaning when used in this Second Supplement. To the extent that there is any inconsistency between any statement in this Second Supplement and any other statement in or incorporated by reference in the Base Prospectus, the statements in this Second Supplement will prevail.

Save as disclosed in this Second Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information contained or incorporated in the Base Prospectus which is capable of affecting the assessment of the Notes to be issued under the Programme since the publication of the Base Prospectus.

TABLE OF CONTENTS

FRONT PAGE.....	3
GENERAL DESCRIPTION OF THE PROGRAMME	4
DOCUMENTS INCORPORATED BY REFERENCE.....	5
FORM OF FINAL TERMS.....	11
GENERAL INFORMATION	13
PERSONS RESPONSIBLE FOR THE INFORMATION GIVEN IN THE SUPPLEMENT	14

FRONT PAGE

The heading and the first paragraph appearing on page 1 of the Base Prospectus are hereby deleted and replaced with the following:

"

L'ORÉAL

L'Oréal
€15,000,000,000
Euro Medium Term Note Programme

Under the Euro Medium Term Note Programme (the "**Programme**") described in this base prospectus (the "**Base Prospectus**"), L'Oréal (the "**Issuer**"), subject to compliance with all relevant laws, regulations and directives, may from time to time issue Euro Medium Term Notes (the "**Notes**"). The aggregate nominal amount of Notes outstanding will not at any time exceed €15,000,000,000 (or the equivalent in other currencies)."

GENERAL DESCRIPTION OF THE PROGRAMME

The item entitled "Size" of the section entitled "General Description of the Programme" appearing on page 7 of the Base Prospectus is hereby deleted in its entirety and replaced with the following:

"Up to €15,000,000,000 (or the equivalent in other currencies at the date of issue) aggregate nominal amount of Notes outstanding at any one time. The amount of the Programme may be increased in accordance with the terms of the Dealer Agreement."

DOCUMENTS INCORPORATED BY REFERENCE

The section entitled "*Documents Incorporated by Reference*" appearing on pages 23 to 30 of the Base Prospectus shall be deleted and replaced in its entirety with the following:

"This Base Prospectus should be read and construed in conjunction with the sections identified in the cross-reference table below of the following documents (see hyperlinks in [blue](#)), which have been previously filed with the AMF:

- a) the [Issuer's press release dated 8 December 2025](#) in the French language relating to the Issuer's additional investment in Galderma (the "**Additional Investment in Galderma Press Release**");
- b) the [Issuer's press release dated 21 October 2025](#) in the French language relating to the Issuer's quarterly financial information as at 30 September 2025 (the "**Quarterly Information Press Release as at 30 September 2025**");
- c) the [Issuer's press release dated 19 October 2025](#) in the French language relating to the announcement of a long-term strategic partnership in luxury beauty and wellness between Kering and L'Oréal ("**Kering and L'Oréal long-term strategic partnership Press Release**");
- d) the [Issuer's half-year financial report for 2025](#) in the French language, which includes the unaudited condensed consolidated financial statements of the Issuer for the six-month period ended 30 June 2025 and the limited review report of the statutory auditors thereon (the "**2025 Half Year Financial Report**");
- e) the Issuer's [2024 universal registration document](#) (*document d'enregistrement universel 2024*) in the French language filed with the AMF under registration N° D. 25-0138, dated 24 March 2025 (the "**2024 Universal Registration Document**");
- f) the Issuer's [2023 universal registration document](#) (*document d'enregistrement universel 2023*) in the French language filed with the AMF under registration N° D. 24-0139, dated 19 March 2024 (the "**2023 Universal Registration Document**");
- g) the section "Terms and Conditions of the Notes" (the "**2023 Conditions**") of the base prospectus of the Issuer dated 9 May 2023 which received approval no. 23-147 from the AMF on 9 May 2023 (the "[2023 Base Prospectus](#)"); and
- h) the section "Terms and Conditions of the Notes" (the "**2024 Conditions**") of the base prospectus of the Issuer dated 3 May 2024 which received approval no. 24-137 from the AMF on 3 May 2024 (the "[2024 Base Prospectus](#)").

Such documents shall be incorporated in and form part of this Base Prospectus, save that any statement contained in a document which is incorporated by reference herein shall be modified or superseded for the purpose of this Base Prospectus to the extent that a statement contained herein modifies or supersedes such earlier statement (whether expressly, by implication or otherwise). Any statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this Base Prospectus.

The information contained in the documents incorporated by reference that is not included in the cross-reference list is either not relevant for the investor or is covered elsewhere in the Base Prospectus. For the avoidance of doubt, "Not Applicable" in the cross-reference table below means that the information is not relevant for the purposes of Annex 7 of the Commission Delegated Regulation (EU) 2019/980 implementing the Prospectus Regulation, as amended (the "**Annex**").

The documents incorporated by reference in this Base Prospectus are available on the website of the Issuer (www.loreal-finance.com) and, save for the 2025 Half Year Financial Report, the Kering and L'Oréal long-term strategic partnership Press Release, the Quarterly Information Press Release as at 30 September 2025 and the Additional Investment in Galderma Press Release are available on the website of the AMF (www.amf-france.org). This Base Prospectus and any supplement thereto will also be available on the website of the AMF (www.amf-france.org). Non-official English translations of (i) the Additional Investment in Galderma Press Release, (ii) the Quarterly Information Press Release as at 30 September 2025, (iii) the Kering and L'Oréal long-term strategic partnership Press Release, (iv) the 2025 Half Year Financial Report, (v) the 2024 Universal Registration Document and (vi) the 2023 Universal Registration Document are available on the website of the Issuer (www.loreal-finance.com). These documents are available for information purposes only and are not incorporated by reference in this Base Prospectus. The only binding versions are the French language versions filed with the AMF.

The information on the website of the Issuer (www.loreal-finance.com) does not form part of this Base Prospectus unless that information is incorporated by reference into this Base Prospectus.

The following tables cross-reference the pages of this Base Prospectus to the documents incorporated by reference with the main heading required under the Annex.

Rule	Annex 7 of the Commission Delegated Regulation (EU) 2019/980, as amended	Additional Investment in Galderma Press Release (page number)	Quarterly Information Press Release as at 30 September 2025 (page number)	Kering and L'Oréal long-term strategic partnership Press Release (page number)	2025 Half Year Financial Report (page number)	2024 Universal Registration Document (page number)	2023 Universal Registration Document (page number)
3	RISK FACTORS						
3.1	<p>A description of the material risks that are specific to the issuer and that may affect the issuer's ability to fulfil its obligations under the securities, in a limited number of categories, in a section headed "Risk Factors".</p> <p>In each category the most material risks, in the assessment of the issuer, offeror or person asking for admission to trading on a regulated market, taking into account the negative impact on the issuer and the probability of their occurrence, shall be set out first. The risk factors shall be corroborated by the content of the registration document.</p>				10	172 to 185	
4	INFORMATION ABOUT THE ISSUER						
4.1	History and development of the Issuer					18	
4.1.1	The legal and commercial name of the issuer					386	
4.1.2	The place of registration of the issuer, its registration number and legal entity identifier ('LEI').					386	
4.1.3	The date of incorporation and the length of life of the issuer, except where the period is indefinite.					386	

4.1.4	The domicile and legal form of the issuer, the legislation under which the issuer operates, its country of incorporation, the address, telephone number of its registered office (or principal place of business if different from its registered office) and website of the issuer, if any, with a disclaimer that the information on the website does not form part of the Base Prospectus unless that information is incorporated by reference into the Base Prospectus.					386, outside back cover	
4.1.5	Any recent events particular to the issuer and which are to a material extent relevant to an evaluation of the issuer's solvency.		1 to 7 and 10		9 and 10	Not applicable	
5	BUSINESS OVERVIEW						
5.1	Principal activities						
5.1.1	A brief description of the issuer's principal activities stating the main categories of products sold and/or services performed.					16 to 19, 26 to 29, 32	
5.1.2	The basis for any statements made by the issuer regarding its competitive position.					24 to 25	
6	ORGANISATIONAL STRUCTURE						
6.1	If the issuer is part of a group, a brief description of the group and the issuer's position within the group. This may be in the form of, or accompanied by, a diagram of the organisational structure if this helps to clarify the structure.					8 to 29, 372 to 375 and 379	
6.2	If the Issuer is dependent upon other entities within the group, this must be clearly stated together with an explanation of this dependence.					15	

8	PROFIT FORECASTS OR ESTIMATES					Not Applicable	
9	ADMINISTRATIVE, MANAGEMENT, AND SUPERVISORY BODIES						
9.1	Names, business addresses and functions within the issuer of the following persons and an indication of the principal activities performed by them outside of that issuer where these are significant with respect to that issuer: (a) members of the administrative, management or supervisory bodies; and (b) partners with unlimited liability, in the case of a limited partnership with a share capital.					11 to 14, 66 to 79 and 81	
9.2	Administrative, management, and supervisory bodies conflicts of interests. Potential conflicts of interests between any duties to the issuer, of the persons referred to in item 9.1, and their private interests and or other duties must be clearly stated. In the event that there are no such conflicts, a statement to that effect must be made.					56, 64	
10	MAJOR SHAREHOLDERS						
10.1	To the extent known to the issuer, state whether the issuer is directly or indirectly owned or controlled and by whom and describe the nature of such control and describe the measures in place to ensure that such control is not abused.					11 and 391	

10.2	A description of any arrangements, known to the issuer, the operation of which may at a subsequent date result in a change in control of the issuer.					Not Applicable	
11	FINANCIAL INFORMATION CONCERNING THE ISSUER'S ASSETS AND LIABILITIES, FINANCIAL POSITION AND PROFITS AND LOSSES						
11.1	Historical financial information						
11.1.1	Historical financial information covering the latest two financial years (at least 24 months) or such shorter period as the issuer has been in operation and the audit report in respect of each year.				12 to 36 (unaudited) and 37 (limited review report)	285 to 351	291 to 360
11.1.2	Change of accounting reference date.					Not Applicable	Not Applicable
11.1.3	Accounting standards.				19	292 to 293	298 and 299
11.1.4	Where the audited financial information is prepared according to national accounting standards, the financial information must include at least the following: (a) the balance sheet; (b) the income statement; (c) the accounting policies and explanatory notes.					Not Applicable	Not Applicable
11.1.5	Consolidated financial statements If the issuer prepares both stand-alone and consolidated financial statements, include at least the consolidated financial statements in the registration document.				12 to 36	285 to 342	291 to 350
11.1.6	Age of financial information					288	294

	The balance sheet date of the last year of audited financial information may not be older than 18 months from the date of the registration document						
11.2	Auditing of historical financial information						
11.2.1	The historical financial information must be independently audited. The audit report shall be prepared in accordance with the Directive 2014/56/EU and Regulation (EU) No 537/2014.				37 (limited review report)	347 to 351	356 to 360
11.2.1a	Where audit reports on the historical financial information have been refused by the statutory auditors or where they contain qualifications, modifications of opinion, disclaimers or an emphasis of matter, the reason must be given, and such qualifications, modifications, disclaimers or emphasis of matter must be reproduced in full.					Not Applicable	Not Applicable
11.2.2	Indication of other information in the registration document which has been audited by the auditors.					Not Applicable	Not Applicable
11.2.3	Where financial information in the registration document is not extracted from the issuer's audited financial statements state the source of the data and state that the data is not audited.					Not Applicable	Not Applicable
11.3	Legal and arbitration proceedings						
11.3.1	Information on any governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware), during a period covering at least the previous 12 months which may have or have had in the recent past significant effects				34 and 35	183 and 184; 336 to 338	

	on the Issuer and/or group's financial position or profitability, or provide an appropriate negative statement.						
11.4	Significant changes in the Issuer's financial position						
11.4.1	A description of any significant change in the financial position of the group which has occurred since the end of the last financial period for which either audited financial information or interim financial information have been published, or provide an appropriate negative statement	1	8	1 and 2			
12	MATERIAL CONTRACTS						
12.1	A brief summary of all material contracts that are not entered into in the ordinary course of the issuer's business, which could result in any group member being under an obligation or entitlement that is material to the issuer's ability to meet its obligations to security holders in respect of the securities being issued.					Not Applicable	

The 2023 Conditions and the 2024 Conditions are incorporated by reference in this Base Prospectus for the purpose only of further issues of Notes to be assimilated (*assimilées*) and form a single series with Notes already issued under the 2023 Base Prospectus or the 2024 Base Prospectus, as the case may be. Non-incorporated parts of the 2023 Base Prospectus and the 2024 Base Prospectus are not relevant for investors.

EMTN previous conditions	
2023 Conditions	Pages 31 to 63 of the 2023 Base Prospectus
2024 Conditions	Pages 30 to 78 of the 2024 Base Prospectus

FORM OF FINAL TERMS

The final terms' heading of the section entitled "Form of Final Terms" appearing on page 92 of the Base Prospectus is hereby deleted and replaced with the following:

"Final Terms dated [•]

L'Oréal

[Logo, if document is printed]

Legal Entity Identifier (LEI) of the Issuer: 529900J11GG6F7RKVI53

**Issue of [Aggregate Nominal Amount of Tranche] [Title of Notes]
under the 15,000,000,000
Euro Medium Term Note Programme**

Series No.: [•]

Tranche No.: [•]

Issue Price: [•] per cent.

[Name(s) of Dealer(s)]"

The item entitled "Purpose of Final Terms" in the section entitled "Form of Final Terms" appearing on page 102 of the Base Prospectus is hereby deleted and replaced with the following:

"[PURPOSE OF FINAL TERMS

These Final Terms comprise the final terms required for the admission to trading on the [*specify relevant regulated market*] of the Notes described herein pursuant to the €15,000,000,000 Euro Medium Term Note Programme of L'Oréal.]"

GENERAL INFORMATION

On pages 112 and 113 of the Base Prospectus, paragraphs 3, 5 and 11 of the "*General Information*" section shall be deleted and replaced in their entirety by the below paragraphs:

"3. The Issuer has obtained all necessary consents, approvals and authorisations in the Republic of France in connection with the update of the Programme. For this purpose, on 5 December 2025, the Board of Directors (*Conseil d'administration*) of the Issuer has authorised for a duration of one year from 5 December 2025, the issue of Notes up to an aggregate nominal amount of €15,000,000,000."

"5. Except as disclosed in the "*Documents Incorporated by Reference*" section of this Base Prospectus, there has been no significant change in the financial position or financial performance of Issuer or the Group since 30 September 2025, and no material adverse change in the prospects of the Issuer since 31 December 2024."

"11. The following documents:

- (i) the articles of association (*statuts*) of the Issuer;
- (ii) this Base Prospectus together with any supplement to this Base Prospectus; and
- (iii) the documents incorporated by reference, including:
 - a. the Issuer's 2024 universal registration document (*document d'enregistrement universel 2024*) in the French language filed with the AMF under registration N° D. 25-0138, dated 24 March 2025;
 - b. the Issuer's 2023 universal registration document (*document d'enregistrement universel 2023*) in the French language filed with the AMF under registration N° D.24-0139, dated 19 March 2024;
 - c. the 2025 Half Year Financial Report;
 - d. the Kering and L'Oréal long-term strategic partnership Press Release;
 - e. the Quarterly Information Press Release as at 30 September 2025; and
 - f. the Additional Investment in Galderma Press Release,

can be inspected on the website of the Issuer (www.loreal-finance.com).

This Base Prospectus, any supplement thereto and, save for the 2025 Half Year Financial Report, the Kering and L'Oréal long-term strategic partnership Press Release, the Quarterly Information Press Release as at 30 September 2025 and the Additional Investment in Galderma Press Release, the documents incorporated by reference in this Base Prospectus are available on the website of the AMF (www.amf-france.org).

Non-official English translations of (i) the 2023 Universal Registration Document, (ii) the 2024 Universal Registration Document, (iii) the 2025 Half Year Financial Report, (iv) the Kering and L'Oréal long-term strategic partnership Press Release, (v) the Quarterly Information Press Release as at 30 September 2025 and (vi) Additional Investment in Galderma Press Release are available on the website of the Issuer (www.loreal-finance.com). These documents are available for information purposes only and are not incorporated by reference in this Base Prospectus. The only binding versions are the French language versions filed with the AMF.

The Agency Agreement will be available for inspection during usual business hours on any week day except Saturdays, Sundays and public holidays at the primary business office of the Issuer."

PERSONS RESPONSIBLE FOR THE INFORMATION GIVEN IN THE SUPPLEMENT

To the best knowledge of the Issuer, the information contained in this Second Supplement is in accordance with the facts and contains no omission likely to affect the import of such information.

L'Oréal
14 rue Royale
75008 Paris
France

Duly represented by:
Christophe Babule, Chief Financial Officer
(*Directeur Général Administration et Finances*)
Dated 19 December 2025



Autorité des marchés financiers

This Second Supplement to the Base Prospectus has been approved on 19 December 2025 by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129, as amended. The AMF has approved this Second Supplement after having verified that the information contained in the Base Prospectus is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129, as amended. Approval does not imply that the AMF has verified the accuracy of this information

This approval should not be considered as a favourable opinion on the Issuer and on the quality of the Notes described in this Second Supplement. Investors should make their own assessment of the opportunity to invest in the Notes.

This Second Supplement has been given the following approval number: 25-488.